BC Extra | Jun 7, 2014
Financial News

Radius raises $52 million in IPO

Radius Health Inc. (NASDAQ:RDUS) raised $52 million through the sale of 6.5 million shares at $8 in an IPO underwritten by Jefferies; Cowen; Canaccord; and Cantor Fitzgerald. On Monday, Radius said it planned to sell...
BC Extra | Jun 3, 2014
Financial News

Radius revives IPO plans

Radius Health Inc. (Cambridge, Mass.) proposed to raise $52 million through the sale of 6.5 million shares at $8 in an IPO on NASDAQ underwritten by Jefferies; Cowen; Canaccord; and Cantor Fitzgerald. If the offering...
BC Extra | May 10, 2014
Financial News

Radius postpones IPO

Two Wall Street sources told BioCentury that Radius Health Inc. (Cambridge, Mass.) postponed its IPO on NASDAQ for the second time, citing market conditions. The company declined to comment, saying it is in a quiet...
BC Extra | Apr 25, 2014
Financial News

Radius sets IPO range

Radius Health Inc. (Cambridge, Mass.) amended its IPO on NASDAQ and now plans to sell 5 million shares at $14-$16. At the $15 midpoint, the company would raise $75 million and be valued at $389.3...
BC Week In Review | Feb 17, 2014
Clinical News

BA058-transdermal: Phase II data

Top-line data from a double-blind, international Phase II trial in 250 postmenopausal women with osteoporosis showed that once-daily 50, 100 and 150 µg doses of transdermal abaloparatide applied to the skin and removed after 5...
BC Extra | Apr 26, 2013
Financial News

Radius raises $43 million in series B

Radius Health Inc. (Cambridge, Mass.) raised $43 million in a series B round led by new investor F2 Biosciences. Existing investors Biotech Growth; MPM Capital; Brookside Capital; MPM Bio IV NVS Strategic Fund; and BB...
BC Week In Review | Mar 18, 2013
Clinical News

BA058-SC: Completed Phase III enrollment

Radius completed enrollment of 2,400 patients in a double-blind, placebo-controlled, international Phase III trial comparing 80 µg BA058-SC daily vs. 20 µg teriparatide daily. BA058-TD, a transdermal formulation of BA058-SC, is in Phase II testing...
BC Week In Review | Jan 14, 2013
Clinical News

BA058-transdermal: Completed Phase II enrollment

Radius completed enrollment of 250 postmenopausal women with osteoporosis in a double-blind, placebo-controlled, international Phase II trial comparing 50, 100 and 150 µg BA058-TD once daily vs. once-daily 80 µg subcutaneous BA058-Injection ( BA058-SC ) for 6...
BC Week In Review | Jan 14, 2013
Company News

Radius Health, 3M deal

Radius and 3M amended a 2011 deal to develop a transdermal formulation of BA058. Radius said the amendment covers exclusive development of bone anabolics, including parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP), for osteoporosis....
BC Week In Review | Oct 8, 2012
Clinical News

BA058-transdermal: Phase II started

Radius began a double-blind, placebo-controlled, international Phase II trial to compare once-daily 50, 100 and 150 µg BA058-TD vs. once-daily 80 µg subcutaneous BA058-Injection ( BA058-SC ) for 6 months in about 240 postmenopausal women with osteoporosis....
Items per page:
1 - 10 of 11